B
Boundless Bio, Inc.
BOLDCIK 0001782303NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-58.20M
Total Assets
$157.06M
Equity
$98.65M
Shares Out
22.41M
Op. Cash Flow
$-46.70M
Business
Boundless Bio, Inc. is a clinical-stage oncology company that develops therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers. It designs and develops small molecule ecDNA-directed therapeutic candidates (ecDTx), including lead CHK1 inhibitor BBI-355, a CNS-penetrant CHK1 candidate BBI-098, and a kinesin-directed program, and it deploys an ecDNA diagnostic called ECHO. Its key capabilities include the proprietary Spyglass target identification and validation platform, internal drug discovery and clinical development programs, and a precision medicine diagnostic. The company conducts clinical trials and intends to commercialize therapies in major markets including the United States, European Union, and Japan.
Summary from filing dated 2025-03-27
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 45 | 55 | 43 | |
| General and administrative | 19 | 18 | 12 | |
| Total operating expenses | 64 | 73 | 55 | |
| Loss from operations | −64 | −73 | −55 | |
| Interest income | 5 | 8 | 5 | |
| Other income (expense), net | −2,000 | 12,000 | 80,000 | |
| Total other income, net | 5 | 8 | 5 | |
| Net loss | −58 | −65 | −49 | |
| Unrealized gain (loss) on short-term investments | −57,000 | 81,000 | 438,000 | |
| Comprehensive loss | −58 | −65 | −49 | |
| Net loss per share - basic | −2.6 | −3.85 | −40.65 | |
| Net loss per share - diluted | −2.6 | −3.85 | −40.65 | |
| Shares used in calculation, basic | 22 | 17 | 1 | |
| Shares used in calculation, diluted | 22 | 17 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 18 | 27 | 24 | |
| Short-term investments | 90 | 126 | 97 | |
| Prepaid expenses and other current assets | 2 | 2 | 3 | |
| Total current assets | 110 | 154 | 124 | |
| Property and equipment, net | 3 | 4 | 3 | |
| Right-of-use asset, net | 44 | 47 | 2 | |
| Restricted cash | 560,000 | 560,000 | 560,000 | |
| Other assets | 13,000 | 99,000 | 555,000 | |
| Total assets | 157 | 206 | 130 | |
| Accounts payable and accrued liabilities | 7 | 5 | 4 | |
| Accrued compensation | 3 | 3 | 3 | |
| Lease liabilities, current portion | 3 | — | 2 | |
| Total current liabilities | 13 | 8 | 9 | |
| Lease liabilities, non-current | 46 | 48 | — | |
| Total liabilities | 58 | 56 | 9 | |
| Commitments and contingencies (Notes 8) | — | — | — | |
| Preferred stock, $0.0001 par value; 70,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 700,000 shares authorized, 22,407 shares issued and outstanding as of December 31, 2025; 700,000 shares authorized, 22,300 shares issued and outstanding as of December 31, 2024 | 2,000 | 2,000 | 0 | |
| Additional paid-in-capital | 358 | 352 | 9 | |
| Accumulated other comprehensive income | 64,000 | 121,000 | 40,000 | |
| Accumulated deficit | −260 | −201 | −136 | |
| Total stockholders' equity | 99 | 151 | −127 | |
| Total liabilities and stockholders' equity | 157 | 206 | 130 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Stock-based compensation | 6 | 8 | 3 | |
| Depreciation and amortization | 1 | 1 | 957,000 | |
| Accretion of investments, net | −3 | −5 | −3 | |
| Non-cash lease expense | 3 | 3 | 2 | |
| Other | — | 102,000 | 25,000 | |
| Prepaid expenses and other assets | 332,000 | −302,000 | 85,000 | |
| Accounts payable and accrued liabilities | 2 | 775,000 | 2 | |
| Operating lease liabilities | 1 | −2 | −3 | |
| Net cash used in operating activities | −47 | −61 | −47 | |
| Purchases of investments | −175 | −208 | −160 | |
| Maturities of investments | 213 | 185 | 122 | |
| Purchases of property and equipment | −546,000 | −3 | −633,000 | |
| Net cash provided by (used in) investing activities | 38 | −26 | −38 | |
| Proceeds from the issuance of common stock from initial public offering, net of discounts | — | 93 | — | |
| Payments of common stock offering costs | — | −3 | — | |
| Proceeds from the exercise of stock options | — | 62,000 | 182,000 | |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 141,000 | 110,000 | — | |
| Net cash provided by financing activities | 141,000 | 90 | 98 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | −9 | 3 | 13 | |
| Change in unpaid common stock issuance costs | — | −197,000 | 197,000 | |
| Addition to right-of-use assets obtained in exchange for lease obligation | — | 48 | 282,000 | |
| Decrease to right-of-use assets due to remeasurement of lease obligation | −92,000 | — | −723,000 | |
| Vesting of early exercised stock options | — | 6,000 | 92,000 | |
| Unpaid property and equipment purchases | — | 400,000 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro